- Home
- IMAB vs EHAB Comparison
IMAB vs EHAB Comparison
Compare IMAB & EHAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- EHAB
- Stock Information
- Founded
- IMAB 2014
- EHAB 2014
- Country
- IMAB United States
- EHAB United States
- Employees
- IMAB N/A
- EHAB N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- EHAB Hospital/Nursing Management
- Sector
- IMAB Health Care
- EHAB Health Care
- Exchange
- IMAB Nasdaq
- EHAB Nasdaq
- Market Cap
- IMAB 384.6M
- EHAB 409.1M
- IPO Year
- IMAB 2020
- EHAB N/A
- Fundamental
- Price
- IMAB $4.38
- EHAB $7.79
- Analyst Decision
- IMAB Strong Buy
- EHAB Buy
- Analyst Count
- IMAB 4
- EHAB 3
- Target Price
- IMAB $6.75
- EHAB $8.67
- AVG Volume (30 Days)
- IMAB 2.1M
- EHAB 438.7K
- Earning Date
- IMAB 11-02-2025
- EHAB 11-05-2025
- Dividend Yield
- IMAB N/A
- EHAB N/A
- EPS Growth
- IMAB N/A
- EHAB N/A
- EPS
- IMAB N/A
- EHAB N/A
- Revenue
- IMAB N/A
- EHAB $1,037,800,000.00
- Revenue This Year
- IMAB N/A
- EHAB $4.95
- Revenue Next Year
- IMAB N/A
- EHAB $4.33
- P/E Ratio
- IMAB N/A
- EHAB N/A
- Revenue Growth
- IMAB N/A
- EHAB N/A
- 52 Week Low
- IMAB $0.60
- EHAB $6.47
- 52 Week High
- IMAB $5.90
- EHAB $10.91
- Technical
- Relative Strength Index (RSI)
- IMAB 54.65
- EHAB 51.75
- Support Level
- IMAB $4.17
- EHAB $7.77
- Resistance Level
- IMAB $4.69
- EHAB $7.96
- Average True Range (ATR)
- IMAB 0.53
- EHAB 0.20
- MACD
- IMAB -0.12
- EHAB -0.01
- Stochastic Oscillator
- IMAB 25.44
- EHAB 28.57
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About EHAB Enhabit Inc.
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services for adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing a life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.